Signs point in that direction, the Pacific Coast Business Times says. After all, the company not only announced its first dividend earlier this year -- and that's one of the hallmarks of a Big Pharma stock -- but has now embarked on a multibillion-dollar stock-buyback plan.
FULL ARTICLE AT The Motley Fool